

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **China Medical & HealthCare Group Limited**

*(Incorporated in Bermuda with limited liability)*

**(Stock Code: 383)**

### **PROFIT WARNING**

This announcement is made by the Company pursuant to Rule 13.09 of the Listing Rules and the Inside Information Provisions under Part XIVA of the SFO.

The Board wishes to inform the shareholders of the Company and potential investors that based on its preliminary review on the relevant unaudited consolidated management accounts of the Group for the year ended 31 December 2021 and information currently available, the Group is expected to record an increase in loss attributable to shareholders of the Company for the year ended 31 December 2021 in the range of approximately HK\$130 million to HK\$190 million (subject to any further impairment or other adjustments) as compared with a loss of approximately HK\$111.9 million in 2020. This was mainly due to (i) the increase in impairment loss under expected credit loss model of financial assets; (ii) a provision for properties held for sale; and (iii) an impairment loss recognized on goodwill, which were partially off-set by the decreased losses on fair value of investments held for trading and investment properties.

**Shareholders of the Company and potential investors should exercise caution when dealing in the securities of the Company.**

This announcement is made by China Medical & HealthCare Group Limited (the “**Company**”, together with its subsidiaries, collectively the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong) (the “**SFO**”).

The board of directors (the “**Board**”) of the Company wishes to inform the shareholders of the Company and potential investors that based on its preliminary review on the relevant unaudited consolidated management accounts of the Group for the year ended 31 December 2021 and information currently available, the Group is expected to record an increase in loss attributable to shareholders of the Company for the year ended 31 December 2021 in the range of approximately HK\$130 million to HK\$190 million (subject to any further impairment or other adjustments) as compared with a loss of approximately HK\$111.9 million in 2020. This was mainly due to (i) the increase in impairment loss under expected credit loss model of financial assets; (ii) a provision for properties held for sale; and (iii) an impairment loss recognized on goodwill, which were partially off-set by the decreased losses on fair value of investments held for trading and investment properties.

This profit warning announcement is only based on the preliminary review on the relevant unaudited consolidated management accounts of the Group for the year ended 31 December 2021 and information currently available, which have not been confirmed or reviewed by the auditor of the Company, and may be subject to adjustments. The Company is in the process of finalizing the annual results for the year ended 31 December 2021 and shareholders of the Company and potential investors are advised to read carefully the annual results announcement of the Company for the year ended 31 December 2021, which is expected to be released before the end of March 2022.

**Shareholders of the Company and potential investors should exercise caution when dealing in the securities of the Company.**

By Order of the Board  
**China Medical & HealthCare Group Limited**  
**Chong Sok Un**  
*Deputy Chairman*

Hong Kong, 18 March 2022

*As at the date of this announcement, the Board comprises:*

*Executive Directors*

*Ms. Chong Sok Un (Deputy Chairman), Mr. Guo Meibao and Mr. Zhou Haiying*

*Non-Executive Directors*

*Mr. Zheng Zhen and Mr. Lai Hin Wing Henry Stephen*

*Independent Non-Executive Directors*

*Mr. Zhang Jian, Dr. Xia Xiaoning, Dr. Wong Wing Kuen, Albert and Ms. Yang Lai Sum, Lisa*